Published on

Medicine – Multiple Myeloma

Multiple myeloma is a malignant plasma cell disorder characterised by clonal proliferation of plasma cells within the bone marrow and production of a monoclonal immunoglobulin (paraprotein) or free light chains.

The disease may cause diffuse bone marrow infiltration, focal osteolytic lesions, renal impairment, anaemia and increased susceptibility to infections.

It predominantly affects older adults, with a median age at diagnosis of approximately 69–70 years.

Important Clinical Principle

Multiple myeloma is a plasma cell malignancy that causes organ damage through bone marrow infiltration, abnormal monoclonal protein production and increased osteoclast-mediated bone resorption.

1. Aetiology and Pathophysiology

Multiple myeloma develops from malignant transformation of a plasma cell clone, usually preceded by monoclonal gammopathy of undetermined significance (MGUS).

The malignant plasma cells accumulate within the bone marrow and produce monoclonal immunoglobulins or free light chains.

Mechanisms of Organ Damage

  • Bone destruction: Myeloma cells stimulate osteoclast activity and suppress osteoblast activity, producing osteolytic lesions.
  • Anaemia: Bone marrow infiltration and impaired erythropoiesis.
  • Renal impairment: Frequently caused by free light-chain cast nephropathy; hypercalcaemia, dehydration and amyloidosis may also contribute.
  • Infection: Suppression of normal immunoglobulin production, known as immunoparesis.
  • Amyloidosis: Some plasma cell clones produce light chains capable of forming AL amyloid deposits.

Pathophysiology Flowchart

Clonal Plasma Cell Proliferation Bone Marrow Infiltration Paraprotein / free light-chain production Organ and Tissue Damage Bone, kidneys, blood and immunity CRAB Features C – Hypercalcaemia R – Renal impairment A – Anaemia B – Bone lesions

2. Types of Paraproteins

Myeloma cells produce monoclonal immunoglobulins or free light chains. The major types are:

Paraprotein Type Approximate Frequency
IgG50–60%
IgA20–25%
Light-chain-only myeloma15–20%
IgD, IgE, IgM or other rare typesUncommon

The exact proportions vary between populations and diagnostic series.

Important Clarification: A small proportion of patients have oligosecretory or non-secretory myeloma. Serum protein electrophoresis alone may therefore fail to demonstrate a clear monoclonal spike.

3. Clinical Features

A. Bone Pain

Bone pain is one of the most common presenting symptoms of multiple myeloma.

Typical sites include:

  • Vertebral column, particularly the lower back.
  • Ribs.
  • Pelvis.
  • Shoulders.
  • Long bones.

Complications include pathological fractures, vertebral compression fractures and spinal cord compression.

B. Renal Impairment

Renal dysfunction may result from:

  • Free light-chain cast nephropathy.
  • Hypercalcaemia.
  • Dehydration.
  • AL amyloidosis.
  • Monoclonal immunoglobulin deposition disease.
  • Nephrotoxic medications.

C. Anaemia

Anaemia is usually normocytic and normochromic.

Symptoms include fatigue, pallor, weakness and exertional dyspnoea.

D. Recurrent Infections

Patients are particularly susceptible to bacterial respiratory and urinary tract infections because normal immunoglobulin production is suppressed.

E. Amyloidosis

Associated AL amyloidosis may cause:

  • Nephrotic syndrome.
  • Restrictive cardiomyopathy.
  • Peripheral neuropathy.
  • Macroglossia.

4. CRAB Features

The classic manifestations of myeloma-related end-organ damage are remembered using the mnemonic CRAB.

Letter Feature Clinical Manifestations
CHypercalcaemiaThirst, constipation, confusion, dehydration
RRenal impairmentReduced renal function, acute kidney injury
AAnaemiaFatigue, pallor, dyspnoea
BBone lesionsOsteolytic lesions, bone pain, pathological fractures

CRAB Illustration

C Hypercalcaemia Thirst, constipation, confusion R Renal Impairment Light-chain nephropathy and renal dysfunction A Anaemia Fatigue, pallor, dyspnoea B Bone Lesions Osteolytic lesions, fractures, bone pain

5. Investigations

A. Blood Investigations

Investigation Typical Finding
Full blood countNormocytic normochromic anaemia
ESROften markedly elevated
Serum calciumMay be elevated
Renal functionElevated creatinine or reduced eGFR
Total serum proteinMay be elevated
AlbuminMay be reduced
Serum protein electrophoresisMonoclonal protein (M-spike), if detectable
Serum immunofixationIdentifies monoclonal immunoglobulin type
Serum free light chainsAbnormal kappa/lambda ratio
Beta-2 microglobulinUsed in prognostic staging

B. Urine Investigations

Bence Jones proteins are monoclonal free immunoglobulin light chains excreted in urine.

Urine protein electrophoresis and immunofixation may identify urinary monoclonal light chains.

A negative urine test does not exclude multiple myeloma.

C. Bone Marrow Examination

Bone marrow aspiration and biopsy may demonstrate:

  • Increased clonal plasma cells.
  • Plasma cell infiltration of the bone marrow.
  • Kappa or lambda light-chain restriction.
  • Cytogenetic abnormalities relevant to prognosis.

A bone marrow clonal plasma cell proportion of at least 10%, or a biopsy-proven plasmacytoma, is part of the standard diagnostic framework for active multiple myeloma.

D. Imaging

Characteristic imaging findings include:

  • Punched-out osteolytic lesions.
  • Vertebral compression fractures.
  • Pathological fractures.
  • Diffuse or focal marrow involvement.

The classical pepper-pot skull appearance refers to multiple small punched-out lesions on skull radiographs.

Modern whole-body low-dose CT, MRI or PET/CT is generally preferred over conventional skeletal surveys for initial assessment.

6. Diagnostic Criteria – SLiM-CRAB

Active multiple myeloma is diagnosed when there are at least 10% clonal bone marrow plasma cells or a biopsy-proven plasmacytoma, together with at least one myeloma-defining event.

These events include CRAB features attributable to the plasma cell disorder or one of three biomarkers remembered by SLiM.

Criterion Myeloma-Defining Finding
SClonal bone marrow plasma cells ≥60%
LiInvolved/uninvolved serum free light-chain ratio ≥100, with involved light chain ≥100 mg/L
MMore than one focal lesion on MRI, each ≥5 mm
CHypercalcaemia meeting diagnostic thresholds
RRenal impairment meeting diagnostic thresholds
AAnaemia meeting diagnostic thresholds
BOne or more qualifying osteolytic bone lesions
Important Clarification: Organ damage must be attributable to the plasma cell disorder. Not every abnormality in a patient with a monoclonal protein is necessarily caused by myeloma.

Diagnostic Flowchart

Suspected Multiple Myeloma Bone pain / anaemia / renal impairment Blood and Urine Investigations Electrophoresis, immunofixation, free light chains Bone Marrow Examination Clonal plasma cells and cytogenetics Whole-Body Imaging CT / MRI / PET-CT as appropriate Apply SLiM-CRAB Criteria Clonal plasma cell disorder + myeloma-defining event

7. Differential Diagnosis

Disorder Distinguishing Feature
MGUSMonoclonal protein without myeloma-defining events; lower clonal burden
Smouldering myelomaHigher clonal burden but no myeloma-defining events
Waldenström macroglobulinaemiaUsually IgM paraprotein with lymphoplasmacytic lymphoma
Metastatic bone malignancyBone lesions without typical clonal plasma cell findings
AL amyloidosisOrgan deposition of amyloidogenic light chains

8. Management of Multiple Myeloma

Treatment depends on symptoms, frailty, renal function, cytogenetic risk, transplant eligibility and access to available therapies.

A. Supportive Treatment

  • Analgesia for bone pain, avoiding nephrotoxic drugs where possible.
  • Appropriate hydration and treatment of hypercalcaemia.
  • Bisphosphonates or denosumab for myeloma-related bone disease when indicated.
  • Blood transfusion for symptomatic severe anaemia.
  • Infection prevention and prompt treatment.
  • Local radiotherapy for selected painful bone lesions or plasmacytomas.
  • Urgent assessment of suspected spinal cord compression.
  • Management of renal impairment, including rapid reduction of light-chain production.

B. Anti-Myeloma Drug Therapy

Modern treatment generally involves combinations of agents such as:

  • Proteasome inhibitors: Bortezomib and carfilzomib.
  • Immunomodulatory drugs: Lenalidomide and pomalidomide.
  • Corticosteroids: Dexamethasone.
  • Monoclonal antibodies: Daratumumab and other agents.
  • Alkylating agents: Cyclophosphamide and melphalan.

A commonly used combination is daratumumab, bortezomib, lenalidomide and dexamethasone (D-VRd), where appropriate and available.

C. Autologous Stem Cell Transplantation

Selected fit patients may undergo high-dose chemotherapy followed by autologous haematopoietic stem cell transplantation.

The procedure uses the patient's own collected stem cells to restore bone marrow function after intensive chemotherapy.

D. Relapsed or Refractory Disease

Depending on prior treatment and eligibility, options may include alternative drug combinations, CAR-T-cell therapy and bispecific antibodies.

Multiple myeloma is generally treatable but not routinely curable, and relapse remains common.

Treatment Flowchart

Active Multiple Myeloma Confirm diagnosis and assess risk Supportive Care Bone, renal, infection and anaemia care Combination Drug Therapy Individualised induction regimen Transplant Eligibility Autologous transplant if appropriate Maintenance and Monitoring Response, relapse and complications

9. Important Complications

  • Pathological fractures.
  • Spinal cord compression.
  • Acute kidney injury and chronic kidney disease.
  • Severe hypercalcaemia.
  • Recurrent or severe infections.
  • AL amyloidosis.
  • Hyperviscosity syndrome, less common than in Waldenström macroglobulinaemia.
  • Venous thromboembolism, including treatment-associated risk.

10. High-Yield Examination Summary

Feature Key Point
DiseaseMalignant plasma cell neoplasm
Typical ageAround 70 years
Most common paraproteinIgG
Bone abnormalityPunched-out osteolytic lesions
Blood filmRouleaux formation may occur
ESROften markedly elevated
Urine proteinBence Jones free light chains
Renal diseaseCommonly light-chain cast nephropathy
Diagnostic mnemonicSLiM-CRAB
Bone marrowClonal plasma cell proliferation
TreatmentCombination anti-myeloma therapy ± autologous stem cell transplantation

11. Key Examination Pearls

  • Multiple myeloma is a plasma cell malignancy producing monoclonal immunoglobulins or free light chains.
  • IgG is the most common paraprotein type.
  • Bone pain, particularly in the back and ribs, is a common presentation.
  • Osteolytic lesions occur because osteoclast activity is increased.
  • Renal impairment commonly results from free light-chain cast nephropathy.
  • Anaemia results from marrow involvement and other disease-related mechanisms.
  • Normal antibody production is suppressed, increasing susceptibility to infection.
  • Bence Jones proteins are monoclonal free light chains in urine.
  • A high ESR and rouleaux formation are supportive but not diagnostic.
  • Diagnosis requires demonstration of a clonal plasma cell disorder and myeloma-defining events.
  • Modern treatment uses combination drug therapy, with autologous stem cell transplantation in eligible patients.
Most Important Examination Point

An older patient presenting with persistent back pain, anaemia, renal impairment, hypercalcaemia and punched-out osteolytic lesions should raise strong suspicion of multiple myeloma. Confirm the diagnosis using monoclonal protein studies, serum free light chains, bone marrow assessment and appropriate imaging.

Clinical Note

Suspected spinal cord compression, severe hypercalcaemia, acute kidney injury or serious infection in a patient with multiple myeloma requires urgent medical assessment. Treatment should be individualised by a specialist haematology team.

Kembara Xtra – Medicine Revision Notes

Image description
0 Comments